During the past decade, Pensacola Lung Group conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Pensacola Lung Group" are "Pulmonary Arterial Hypertension" (1 trials), "Pulmonary Embolism" (1 trials) and "Venous Thrombosis" (1 trials). Many other conditions were trialed in "Pensacola Lung Group" in a lesser frequency.

Most popular intervention types in "Pensacola Lung Group" are "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Apixaban" (1 trials) and "Enoxaparin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Pensacola Lung Group" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Pensacola Lung Group". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Pensacola Lung Group, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Pensacola Lung Group, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".